Excessive production of TNF-α may play a role in the pathogenesis of myositis, and therefore may lead to a therapeutic role for TNF-α inhibitors, such as infliximab or etanercept, in the treatment of IIM [197]. The gene discussed is TNF; the disease is myositis disease.